Key Details
Last Dividend
$1.03Annual ROE
-67.90%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 20, 2024Recent annual earnings:
Mar 20, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Mar 15, 2024Next split:
N/ARecent split:
Mar 22, 2024Analyst ratings
Recent major analysts updates
21 Mar '23 RBC Capital
Sector Perform23 Feb '23 Cowen & Co.
Market Perform23 Feb '23 Cantor Fitzgerald
Neutral23 Feb '23 B of A Securities
Underperform03 Feb '23 Morgan Stanley
Equal-Weight25 Jan '23 BTIG
Neutral18 Jan '23 B of A Securities
Neutral06 Jan '23 SVB Leerink
Market Perform06 Jan '23 RBC Capital
Sector Perform06 Jan '23 BMO Capital
Market PerformScreeners with GRPH included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock
GRPH
Zacks Investment Research16 November 2023
Graphite Bio, Inc. (GRPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FAQ
- What is the primary business of Graphite Bio?
- What is the ticker symbol for Graphite Bio?
- Does Graphite Bio pay dividends?
- What sector is Graphite Bio in?
- What industry is Graphite Bio in?
- What country is Graphite Bio based in?
- When did Graphite Bio go public?
- Is Graphite Bio in the S&P 500?
- Is Graphite Bio in the NASDAQ 100?
- Is Graphite Bio in the Dow Jones?
- When was Graphite Bio's last earnings report?
- When does Graphite Bio report earnings?
- Should I buy Graphite Bio stock now?
What is the primary business of Graphite Bio?
As of March 21, 2024, Graphite Bio, Inc. was acquired by LENZ Therapeutics, Inc., in a reverse merger transaction. Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.
What is the ticker symbol for Graphite Bio?
The ticker symbol for Graphite Bio is NASDAQ:GRPH
Does Graphite Bio pay dividends?
No, Graphite Bio does not pay dividends
What sector is Graphite Bio in?
Graphite Bio is in the Healthcare sector
What industry is Graphite Bio in?
Graphite Bio is in the Biotechnology industry
What country is Graphite Bio based in?
Graphite Bio is headquartered in United States
When did Graphite Bio go public?
Graphite Bio's initial public offering (IPO) was on 25 June 2021
Is Graphite Bio in the S&P 500?
No, Graphite Bio is not included in the S&P 500 index
Is Graphite Bio in the NASDAQ 100?
No, Graphite Bio is not included in the NASDAQ 100 index
Is Graphite Bio in the Dow Jones?
No, Graphite Bio is not included in the Dow Jones index
When was Graphite Bio's last earnings report?
Graphite Bio's most recent earnings report was on 20 March 2024
When does Graphite Bio report earnings?
The date for Graphite Bio's next earnings report has not been announced yet
Should I buy Graphite Bio stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions